Stockscreener 앱 받기
8.80
8.62%
-0.83
시장 영업 전:
8.80
전일 마감가:
$9.63
열려 있는:
$9.63
하루 거래량:
1.05M
Relative Volume:
0.40
시가총액:
$614.36M
수익:
-
순이익/손실:
$-297.11M
주가수익비율:
-1.6956
EPS:
-5.19
순현금흐름:
$-216.95M
1주 성능:
+12.39%
1개월 성능:
-9.65%
6개월 성능:
+40.80%
1년 성능:
-25.04%
1일 변동 폭
$8.80
$10.03
1주일 범위
$7.61
$10.03
52주 변동 폭
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
8.80 | 672.31M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
What are the latest earnings results for Phathom Pharmaceuticals Inc.High-octane financial growth - jammulinksnews.com
Phathom Pharmaceuticals to Host Conference Call for Q2 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 - The Manila Times
Phathom Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
What is Phathom Pharmaceuticals Inc. company’s growth strategyInvest with confidence backed by data - jammulinksnews.com
Is it the right time to buy Phathom Pharmaceuticals Inc. stockAI Powered Review For 2025 - jammulinksnews.com
How does Phathom Pharmaceuticals Inc. generate profit in a changing economyTop Growth Planner That Work - jammulinksnews.com
What are the technical indicators suggesting about Phathom Pharmaceuticals Inc.Rapid market gains - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a growth stock or a value stockDiscover hidden gems in the stock market - jammulinksnews.com
What makes Phathom Pharmaceuticals Inc. stock price move sharplyFree Real-Time Market Predictions - metal.it
How many analysts rate Phathom Pharmaceuticals Inc. as a “Buy”Discover undervalued opportunities early - jammulinksnews.com
What is the risk reward ratio of investing in Phathom Pharmaceuticals Inc. stockMaximize profits with strategic stock selection - jammulinksnews.com
What analysts say about Phathom Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Phathom Pharmaceuticals Inc. Stock Analysis and ForecastConsistent triple returns - jammulinksnews.com
What drives Phathom Pharmaceuticals Inc. stock priceBreakout portfolio performance - jammulinksnews.com
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Phathom Pharmaceuticals' Principal Accounting Officer Robert Charles Sells 1692 Shares at $8.36. - AInvest
When Will Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Turn A Profit? - 富途牛牛
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $17.50 - Defense World
Why Phathom Pharmaceuticals Inc. stock attracts strong analyst attentionShort Squeeze Radar - Newser
How Phathom Pharmaceuticals Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
How To Trade (PHAT) - news.stocktradersdaily.com
Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Profit Outlook - simplywall.st
Phathom Pharmaceuticals: A Path to Profitability and a Billion-Dollar Horizon with Voquezna? - AInvest
Phathom Pharmaceuticals shares rise 1.47% premarket after Cidara Therapeutics closes $402.5 million stock offering. - AInvest
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism - Seeking Alpha
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewswire
FDA Approval for VOQUENZA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC - Quantisnow
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom Pharmaceuticals Announces FDA Correction to Orange - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
1.06%
자본화:
|
볼륨(24시간):